Influence of drug–drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis C virus by Margusino-Framiñán, Luis et al.
Eur J Hosp Pharm. 2021; 28(1):16–21 
Influence of drug–drug interactions on effectiveness and 
safety of direct-acting antivirals against hepatitis C virus 
Luis Margusino-Framiñán,1,2 Purificación Cid-Silva,1,2 Victor Giménez-Arufe,1 
Cristina Mondelo-García,1 Carla Fernández-Oliveira,1 Álvaro Mena-de-Cea,2,3 
Isabel Martín-Herranz,1 Ángeles Castro-Iglesias2,3 
1Pharmacy Service, Universitary Hospital of A Coruña, A Coruña, Spain 
2Division of Clinical Virology, BiomedicalResearch Institute of A Coruña (INIBIC), Universitary Hospital of 
A Coruña(CHUAC), SERGAS, Universidade da Coruña (UDC), A Coruña, Spain 
3Infectious Disease Unit. nternal Medicine Service, Universitary Hospital of A Coruña, A Coruña, Spain 
Abstract 
Objectives. Direct-acting antivirals are the recommended treatment for hepatitis C-infected patients. Drug–
drug interactions with concomitant treatments can cause lack of effectiveness and/or safety. The objective of 
this study is to characterise drug–drug interactions of direct-acting antivirals and to analyse their influence 
both on the effectiveness of antiviral treatment and on the overall safety of pharmacological treatment in 
hepatitis C-infected patients. 
Methods. Observational and prospective cohort study for 3 years in the pharmaceutical care outpatient 
consultation of a general hospital, undertaking detection, evaluation and management of drug–drug 
interactions by clinical pharmacists and physicians. The main outcome measures were sustained virologic 
response at week 12 for effectiveness and serious drug-related adverse events for safety. Multivariate 
statistical analysis applied to: (a) patient basal characteristics related to presence of drug–drug interactions; 
(b) previous antiviral treatments, viral genotype, cirrhosis, decompensations and presence of drug–drug 
interactions related to the effectiveness of direct-acting antivirals. 
Results. Of a total of 1092 patients, the majority of them were men, around 60 years old and HCV-genotype 1 
mono-infected, with a high basal viral load, naive to antiviral treatment, treated with ledipasvir/sofosbuvir 
and without cirrhosis. 24.5% had drug–drug interactions. Proton pump inhibitors were the concomitant drugs 
that caused the most drug–drug interactions. Age ≥65 years and direct-acting antivirals based on protease 
inhibitors were independently related to the presence of drug-drug interactions (p≤0.012). All (100%) of the 
therapeutic recommendations based on detected drug–drug interactions were implemented; 97.7% of patients 
with interactions versus 99.0% without them reached sustained virologic failure (p=0.109). The serious 
adverse events rates were 1.5% and 1.3% in patients with and without drug-drug interactions, respectively 
(p=0.841). 
Conclusions. Drug–drug interactions are frequent among hepatitis C-infected patients receiving treatment 
with direct-acting antivirals. However, the collaboration between physicians and clinical pharmacists makes it 
possible to detect, evaluate, avoid or clinically manage these drug–drug interactions, in order to maintain 
whole treatment therapeutic safety and the effectiveness of direct-acting antivirals. 
  
INTRODUCTION 
Chronic hepatitis C (CHC) is a liver disease caused by the hepatitis C virus (HCV). The WHO 
estimates that around 71 million people are chronically infected with HCV, which is estimated to 
be responsible for approximately 400 000 deaths per year worldwide.1 Interferon (IFN) or 
pegylated interferon (Peg-IFN) alone, or in association with ribavirin (RBV), were initially used to 
treat hepatitis C. In 2011, two direct-acting antivirals (DAAs) were approved for HCV chronic 
infection in combination with Peg-IFN and RBV—telaprevir and boceprevir. Recently, second-
generation  
 
DAAs have been approved, and are currently the treatment of choice for CHC. DAAs act directly 
on HCV replication, interfering with structural or functional protein coding. Sofosbuvir (SOF) and 
dasabuvir (DBV) are inhibitors of RNA-dependent RNA polymerase (NS5B); ledipasvir (LDV), 
ombitasvir (OBV), daclatasvir (DCV), velpatasvir (VEL), elbasvir (ELB) and pibrentasvir (PIB) 
are NS5A protein inhibitors; simeprevir (SMV), paritaprevir (PTV), grazoprevir (GZV), 
glecaprevir (GRZ) and voxilaprevir (VOX) are NS3 or NS4A protein inhibitors.2 The oral 
administration of two or three DAAs over 8–24 weeks, associated or not with RBV, achieves 
therapeutic efficacy rates of around 98% and has demonstrated a high level of clinical safety. For 
these reasons, DAAs are the gold standard of CHC treatment.3  
 
The selection of DAAs against HCV requires an individualised approach based on virus-dependent 
factors (viral genotype, subtype), patient factors (presence of liver cirrhosis) or the previous use of 
antivirals.4 It is also very important to incorporate other factors into this selection, dependent on 
the concomitant pharmacological treatment, such as drug–drug interactions (DDIs). This is due to 
the fact that DAAs share pharmacokinetic pathways, both at the level of transporters and the 
metabolisation/ elimination pathways (cytochrome P450 3A4, P-glycoprotein, breast cancer 
resistance protein or UDP-glucuronyltransferase), with drugs belonging to therapeutic groups 
widely used in patients chronically infected with HCV, such as antiretroviral drugs (ART) against 
the acquired HIV, illicit/ recreational drugs or drugs of abuse, lipid-lowering drugs, central 
nervous system drugs, cardiovascular agents, immunosuppressants, and anticoagulants/ 
antiplatelets or antacids.5,6 Therefore, the potential pharmacokinetic interactions between these 
drugs and the DAAs could cause an increase (and, secondarily, a higher incidence of adverse 
events) or a decrease (with the consequent lack of effectiveness) in their plasma concentrations.7–10  
 
In Spain, DAAs have been marketed as Hospital Use Drugs (H); they can be prescribed only by 
specialist hospital physicians (infectious disease specialists or hepatologists) and can be dispensed 
only by pharmacists in hospital pharmacy services. In addition, the prescription of DAAs requires 
compliance with the National Strategic Plan for the Approach of Hepatitis C in the National 
Health System Statements.11 For this reason, clinical pharmacists specialising in clinical virology 
at our hospital have managed a large number of hepatitis C-infected patients in a monographic 
outpatient consultation,12 carrying out, among other functions, the identification, evaluation and 
follow-up of DDIs13 14 in collaboration with the medical team, as have been established in 
international recommendations.15  
 
The aim of this study is to characterise the DDIs of the DAAs (identification, evaluation and 
clinical management) and analyse their influence, both in the effectiveness of antiviral treatment 
and in the overall safety of pharmacological treatment in hepatitis C-infected patients.  
  
METHODS  
Study design and patient selection  
This is a unicentric, observational, prospective, cohort study of hepatitis C-infected patients who 
started DAA-based antiviral treatment and who had reached week 12 post-treatment. Antiviral 
treatment selection and prescription decisions corresponded to the hospital specialist doctors, 
under usual clinical practice conditions valid during the study period, in accordance with current 
international guidelines.4,5 Adult patients, with CHC, treatment-naïve or treatment-experienced to 
peg-INF+ RBV or DAAs, in all fibrosis stages (F0-4), including patients with decompensated 
cirrhosis or portal hypertension, HIV co-infected patients or liver transplant patients, were 
included.  
Drug–drug interaction variables  
DDIs were identified by the clinical team (clinical pharmacists, hepatologists and infectious 
disease specialists) using the Hep Drug Interactions database of the University of Liverpool,16 
recommended as reference by the European Association for the Study of the Liver (EASL).5 
Where no information was available, Lexicom Drug Interactions,17 IBM Micromedex,18 analysis 
of pharmacokinetic parameters available in the technical data sheet, and consultation with the 
DAA manufacturing laboratory were employed. When a DDI was identified, the drugs and their 
therapeutic group, the enzymes and drug transporters involved, the pharmacokinetic effect 
(indeterminate, increase or decrease in plasma concentration) and interaction potency, that were 
stratified in three levels (high, that contraindicates the drug association, potential, or potential-
weak) were registered; these variables (enzymes, drug transporters, mechanisms, potency, etc) 
were identified through the drug interaction databases previously mentioned.16–18 Therapeutic 
recommendation for the concomitant drug secondary to DDIs was classified into: treatment 
continuation with effectiveness and/or safety monitoring, temporary suspension, administration 
time adjustment, dosage regimen adjustment or therapeutic substitution; both medical doctors and 
clinical pharmacists were responsible, although the latter implemented—without the intervention 
of the medical doctors—those recommendations related to effectiveness and/ or safety monitoring 
when no dose adjustment was required, temporary withdrawal of concomitant drug during 
antiviral treatment or adjustment of the administration schedule.  
Effectiveness and safety variables  
Pharmacological treatment effectiveness and safety follow-up were carried out through SiMON, 
an artificial intelligence monitoring system for CHC patients on treatment, that records 
effectiveness and safety events from clinical data.19  
 
HCV viral load (defined as the RNA HCV in plasma) was determined using the real-time PCR 
technique with the Cobas AmpliPrep platform from Roche. The kit is the HCV Quantitative Test, 
version 2.0. The limits of detection and quantification in plasma (there is no significant difference 
in the serum) were 11 IU/mL (95% CI 10 to 13 IU/mL) for the lower limit of detection (LOD) 
with a 95% positive result rate and 15 UI/mL for LOD with positive results. Viral load 
determinations were made at the baseline, end-of-treatment and 12 weeks after the antiviral 
treatment was completed. Transient elastography was used for the staging of liver fibrosis 
(Fibroscan), stratifying patients according to stiffness results in fibrosis F0-1 (<7.6 kPa), F2 (7.6–
9.5 kPa), F3 (9.6–14.4 kPa) or F4 (>14.4 kPa in HCV mono-infected patients and >14.0 kPa in 
HIV co-infected patients).  
  
Adherence rates were made following continuous measurement of the medication acquisition 
(CMA) method,20 during monthly visits to the Hospital Pharmacy Service where the study was 
conducted, from the beginning to the end of the treatment.  
 
The primary effectiveness endpoint was the sustained virologic response 12 (SVR12), defined as 
RNA-HCV undetectable 12 weeks post-treatment. Secondary efficacy variables were null 
response (lack of RNA-HCV undetectability during DAA treatment) and recurrent (RNA-HCV 
detectable 12 weeks post-treatment in a patient with RNA-HCV undetectable at the end-of-
treatment). The primary safety endpoint was the rate of serious drug-related AEs; secondary 
variables included drug-related AEs, DAA or concomitant treatment withdrawal due to drug-
related AEs, emergency department or hospitalisation secondary to drug-related AEs and death 
secondary to drug-related AEs.  
Statistical analysis  
The intention-to-treat (ITT) evaluable population included all patients who took at least one dose 
of the prescribed treatment. Both baseline variables (demographics, clinical, histological and 
laboratory values and frequencies) and primary or secondary effectiveness and safety end-points 
were analysed by a modified ITT (mITT) analysis, including ITT evaluable population patients 
and excluding patients without quantification of RNA-HCV 12 weeks post-treatment for reasons 
other than treatment failure. Quantitative variables were expressed as mean±SD or as median and 
IQR if their distributions were normal or non-normal, respectively, and were analysed using the 
Student's t-test or the Mann-Whitney U-test, according to data distribution. Qualitative variables 
were expressed as count and percentage, with confidence intervals at 95% (95% CI), and were 
compared using a χ2 test or Fisher's exact test. Primary end-points were expressed as a percentage 
and an exact 95% binomial CI. To determine any baseline factor influence on primary end-points, 
relative risk with a 95% CI (Katz) for cohort studies was calculated using the χ2 association test 
without Yates correction, or Fisher's exact bilateral test according to the number of cases analysed. 
To detect differences between cohorts related to DDI presence based on demographic 
characteristics of the study population and the influence of DDI on virologic response, univariate 
and multivariate analyses were performed. Statistically significant results were considered at a 
value of p<0.05. Statistical analysis was carried out using the Epidat 4.2 programme.  
Ethics approval 
This study complies with the Declaration of Helsinki of Good Clinical Practice. It was classified in 
2015 as ‘Observational Post-Authorisation Study with Human Medicines’ by the Spanish Agency 
of Medicines and Health Products, and it was authorised by the Clinical Research Ethics 
Committee (CREC) of the Regional Health Service (2015). Patients signed an informed consent 
approved by the CREC for their participation in the study and all their data were anonymised.  
RESULTS 
A total of 1092 patients who met the selection criteria were included in the study. The majority of 
patients were men, around 60 years old and HCV mono-infected, genotype 1, with a high basal 
viral load, naïve to antiviral treatment and without cirrhosis. A minority of patients had 
hepatocellular carcinoma or liver transplantation. The most frequent antiviral treatments were 
LDV/SOF±RBV and PTV/OBV/RTV+DBV± RBV for 12 weeks. table 1 summarises the main 
baseline characteristics of the study patients. 
  
Table 1 Demographic and virological characteristics of the study Population 
 
Patients with  
DDI, % (n)  
24.5% (267) 
Patients without  
DDI, % (n)  
75.6% (825) 
P value 
    
Gender    
Males  21.6% (147) 78.4% (534) 0.006 
Females  29.2% (120) 70.8% (291)  
Age, mean±SD (years)  62.3±12.7 56.3±12.5 <0.001 
Age ≥65 years  45.7% (122) 26.2% (226) <0.001 
HCV genotype    
1  83.9% (224) 65.6% (541) <0.001 
2  3.4% (9) 6.3% (52) 0.097 
3  5.2% (14) 15.7% (130) <0.001 
4  7.5% (20) 12.4% (102) 0.037 
Fibrosis stage    
F0-1  15.7% (42) 17.2% (142) 0.640 
F2  29.6% (79) 32.5% (268) 0.419 
F3  22.5% (60) 24.0% (198) 0.669 
F4  32.2% (86) 26.3% (217) 0.073 
HIV co-infection (excluding ART)  14.6% (39) 13.0% (107) 0.495 
HIV co-infection (including ART)  39.3% (105) 5.0 (41) <0.001 
Hepatocellular carcinoma  5.2% (14) 2.9% (24) 0.106 
Liver transplant recipient  5.2% (14) 3.5% (29) 0.207 
HCV viral load, log UI/mL (median)  6.2 (3.7–8.3) 6.2 (2.0–8.9) 0.989 
HCV viral load ≥ 61 UI/mL  59.9% (160) 59.9% (494)  
eGFR ≥60 mL/min  88.8% (237) 92.4% (762) 0.067 
Previous antiviral treatment:    
Naive  75.7% (202) 71.6% (591) 0.201 
Treatment-experienced  24.3% (65) 28.4% (234) 0.201 
Response to previous antiviral treatment:    
Recurrent  52.3% (34) 54.3% (127) 0.779 
Null responder  10.8% (7) 17.1% (40) 0.215 
Regrowth  4.6% (3) 3.4% (8) 0.650 
Partial responder  10.8% (7) 14.1% (33) 0.485 
Unknown  21.5% (14) 11.1% (26) 0.029 
DAAs:    
LDV/SOF±RBV  51.6% (138) 48.7% (402) 0.401 
DCV/LDV±RBV  4.9% (13) 15.8% (130) <0.001 
VEL/SOF±RBV  1.9% (5) 3.2% (26) 0.274 
PTV/OBV/RTV/DBV±RBV  33.7% (90) 17.8% (147) <0.001 
SMV/SOF±RBV  0.8% (2) 2.9% (24) 0.044 
SOF+RBV  0.8% (2) 3.8% (31) 0.013 
PTV/OBV/RTV+RBV  2.6% (7) 1.9% (16) 0.500 
ELB/GRZ  3.7% (10) 5.9% (49) 0.168 
DAAs adherence  99.6% 99.2% 0.707 
    
 
ART, antiretroviral treatment; DAAs, direct-acting antivirals; DBV, dasabuvir; DCV, daclatasvir;DDI, drug–
drug interactions; ELB, elbasvir; GRZ, grazoprevir; LDV, ledipasvir; OBV, ombitasvir; PTV, paritaprevir; 
RBV, ribavirin;RTV, ritonavir; SMV, simeprevir; SOF, sofosbuvir; VEL, velpatasvir; eGFR, estimated 
glomerular filtration rate.  
  
It was found that 24.5% (95% CI 21.9% to 27.0%) of the patients had clinically significant DDIs 
between antiviral and concomitant treatments. A total of 427 DDIs in 267 patients were detected in 
the study population (1.60±0.95 DDIs per patient): 60.7% of patients had one DDI, 27.7% had two 
DDIs and the remainder (11.6%) had three or more DDIs. The mean age of women with DDIs was 
66.7±11.6 years and of men was 58.4±12.3 years (p<0.001). Figure 1 shows the incidence of DDIs 
according to DAAs. The multivariate analysis revealed that only two variables were related to the 
DDIs’ presence, namely having an age ≥65 years (OR 1.8, 95% CI 1.3 to 2.5; p<0.001) and 
antiviral treatment that includes protease inhibitors (OR 1.5, 95% CI 1.1 to 2.1; p=0.012). The 
main therapeutic group that generated clinically significant interactions was A02 (agents for the 
treatment of alterations caused by acids) with more than 25% of the cases, followed by N05 
(psycholeptics) and C10 (lipid modifiers drugs) with percentages higher than 10%; 22.3% of the 
DDIs were generated by omeprazole, followed by amlodipine and atorvastatin, with percentages 
around 5–7%. Although the enzymes involved in the interactions are unknown in more than 25% 
of cases, those that are known include P-glycoprotein and CYP3A4, both with percentages around 
20%. In relation to the potency of the interaction, 82.7% of the cases were of intermediate 
intensity (potential) and only 5.2% of cases contraindicate the concomitant use of the drug and 
antivirals. Two-thirds (67.2%) of the DDIs detected did not affect the DAAs. However, 66.3% of 
the DDIs detected affected the concomitant medication, increasing their pharmacokinetic 
exposure; as a consequence, 54.1% (95% CI 49.3% to 58.9%) of detected DDIs required any 
therapeutic recommendation on the concomitant treatment, mainly temporary withdrawal during 
antiviral treatment (47.3%), administration schedule adjustment (30.7%), dose adjustment (19.0%) 
or therapeutic alternative prescription (3.0%). The remaining detected DDIs (45.9%) were not 
avoided since they only required closer clinical patient monitoring (such as renal function control 
or blood pressure follow-up). The compliance rate for all types of therapeutic recommendations or 
clinical monitoring based on detected DDIs was 100%. The concomitant medication was 
interrupted during the antiviral treatment in 24.6% of cases with PTV/OBV/ RTV+DBV versus 
24.5% with LDV/SOF (p=0.919). The most frequently discontinued drugs as a result of DDIs were 
atorvastatin (79.2%), simvastatin (72.7%) and pantoprazole (45.5%) (p>0.109). table 2 





Figure 1 Incidence of drug–drug interactions according to direct-acting antiviral agent. DBV,dasabuvir; 
DCV, daclatasvir; ELB, elbasvir; GRZ, grazoprevir; LDV, ledipasvir; OBV, ombitasvir; PTV, paritaprevir; 
RBV, ribavirin; RTV, ritonavir; SMV, simeprevir; SOF, sofosbuvir; VEL, velpatasvir  
  
Table 2 Descriptions of direct-acting antiviral drug-drug interactions in the study population 
 % (n) 
  
N° of DDIs  427 
N° DDI/patient, median (range)  1 (1–6) 
N° DDI/patient, mean±SD  1.6±1.0 
Common DDIs by ATC:  
A02 (drugs for acid related disorders) 2 7.2% (116) 
N05 (psycholeptics)  12.9% (55) 
C10 (lipid modifying agents)  11.5% (49) 
C09 (agents acting on the renin-angiotensin system)  9.8% (42) 
C08 (calcium channel blockers)  7.7% (33) 
DDI by concomitant drug (five most frequent)  
Omeprazole  22.3% (95) 
Amlodipine  6.8% (29) 
Atorvastatin  5.6% (24) 
Lorazepam  3.3% (14) 
Alprazolam  3.0% (13) 
Main enzymes and drug transporters involved (five most frequent) N=486 
Indeterminate  25.9% (126) 
P-gp  20.0% (97) 
CYP3A4  19.8% (96) 
OATP1B1  8.8% (43) 
BCRP  8.2% (40) 
Strength of DDI (%)  
Potential interaction  82.7% (353) 
Potential weak interaction  12.2% (52) 
Contraindicated  5.1% (22) 
Concomitant drug pharmacokinetic effect on DAAs  
No effect  67.3% (287) 
Decreased exposure  17.3% (74) 
Indeterminate  8.4% (36) 
Increased exposure  7.0% (30) 
DAA pharmacokinetic effect on concomitant drug  
Increased exposure  66.3% (283) 
No effect  24.1% (103) 
Decreased exposure  7.0% (30) 
Indeterminate  2.6% (11) 
Therapeutic recommendation on concomitant drug  
No dose alteration is required  45.9% (196) 
Temporary withdrawal during antiviral treatment  25.6% (109) 
Administration schedule adjustment  16.6% (71) 
Dose adjustment  10.3% (44) 
Therapeutic alternative prescription  1.6% (7) 
  
 
ATC, anatomical therapeutic classification; BCRP, breast cancer resistant protein; CYP3A4, cytochromo 
P450 3A4;DAA, direct-acting antiviral; DDI, drug–drug interactions; OATP1B1, organic-anion-transporting 
polypeptide 1B1; P-gp, P-glycoprotein.  
  
Regarding the DDIs’ impact on the effectiveness of antiviral treatment, 97.7% (95% CI 95.1% to 
99.1%) of patients with clinically significant interactions, compared with 99.0% (95% 98.0% to 
99.6%) of patients without them, reached SVR12 (p=0.109). The rates of virological non-response 
or relapse patients are clinically and statistically similar in both cohorts, between 1–2% (p≥0.258). 
The multivariate analysis did not detect that being naïve to treatment, viral genotype, liver 
cirrhosis, previous decompensations or presence of DDIs had an influence on the effectiveness of 
DAAs (p>0.25). The incidence of any adverse event degree in patients with versus without DDIs 
was clinically similar: 55.8% versus 48.0% (p=0.027). The rate of serious adverse events was 
1.5% (95% CI 0.4% to 3.8%) and 1.3% (95% CI 0.7% to 2.4%) in patients with and without DDIs 
(p=0.841), respectively. After the initiation of antiviral treatment, the presence of any degree of 
adverse event had not led to antiviral or concomitant treatment withdrawal in either of the two 
cohorts. Likewise, no patient had attended the emergency department or had died as a result of the 
presence of DDIs. In the cohort of DDI patients, one with uncontrollable vomiting had to be 
hospitalised, although the patient already had this symptomatology before the start of antiviral 
treatment and was discharged a few days after being prescribed antiemetic treatment. The adverse 
events of greater incidence in both cohorts have been very similar, highlighting fatigue/asthenia 
and headache, which are the most frequent adverse events of DAAs treatment. The main data 
regarding the effectiveness and safety of patients with and without DDIs is shown in table 3.  
  










 % (n)  % (n)  P value 
      
Virologic response      
SVR12  97.7% (258)  99.0% (804)  0.109 
Null responder  1.1% (3)  0.5 (4)  0.258 
Recurrent  1.1% (3)  1.6% (13)  0.588 
No data  1.1% (3)  1.6% (13)  0.593 
Drug-related adverse events  55.8% (149)  48.0% (396)  0.027 
Drug-related serious adverse events  1.5% (4)  1.3% (11)  0.841 
DAA treatment withdrawal due to drugrelated AE 0.0% (0)  0.0% (0)  >0.999 
Concomitant treatment withdrawal secondary to 
drug-related AE 
0.0% (0)  0.0% (0)  >0.999 
Emergency department admission secondary to 
drug-related AE 
0.0% (0)  0.0% (0)  >0.999 
On-treatment hospitalisation secondary to drug-
related AE 
0.38% (1)  0.0% (0)  0.552 
Death secondary to drug-related AE  0% (0)  0% (0)  >0.999 
Any grade AE with global incidence >2.0%:      
Fatigue/asthenia  32.2% (86)  35.4% (292)  0.342 
Headache  15.0% (40)  20.6% (170)  0.043 
Pruritus  6.4% (17)  6.4% (53)  0.974 
Insomnia  5.6% (15)  5.4% (45)  0.919 
Dry skin and mucous membranes  4.5% (12)  3.6% (30)  0.526 
Nausea  4.1% (11)  3.4% (28)  0.579 
Gastrointestinal upset  3.0% (8)  3.0% (25)  0.977 
Dizziness  3.0% (8)  3.5% (29)  0.684 
Diarrhoea  2.6% (7)  1.0% (8)  0.044 
Myalgia  2.2% (6)  1.7% (14)  0.560 
      
 
AE, adverse events; DAA, direct-acting antiviral; DDIs, drug–drug interactions; SVR12, sustained virologic 
response week 12. 
DISCUSSION  
DDIs are a critical factor in the effectiveness and safety of pharmacological treatments. Given the 
pharmacokinetic characteristics of the new DAAs against HCV, the clinical pharmacist must be 
able to detect, evaluate, and adequately and proactively manage DDIs in the pharmaceutical care 
outpatient consultation, and the DDIs must be evaluated in clinical practice in order to know their 
real impact on the effectiveness and safety of antiviral treatment and the concomitant treatments.  
 
Data from this study reveal that almost a quarter of hepatitis C-infected patients present DDIs, a 
lower percentage than observed in previous studies in cohorts of patients with a similar average 
age, HCV viral genotype, degree of fibrosis and selected DAAs.21 22 The vast majority of the DDIs 
detected had a ‘potential’ effect on the plasma concentrations of the drugs (according to the scale 
used), due mainly to an increase in the exposure of the concomitant medication and, as a 
consequence, temporary suspension, dose adjustment, administration scheme adjustment or the use 
of a therapeutic alternative were required. However, in most cases, DAAs did not modify their 
plasma concentrations and, therefore, modification of the dosage regimen was not required. In a 
very small percentage of cases, the presence of DDIs carried the concomitant medication 
withdrawal. Although univariate analysis revealed that the age and gender of the patient, HCV 
genotype, antiretroviral treatment in HIV co-infected patients and DAAs used could determine the 
presence of DDIs, only age ≥65 years and treatment with protease inhibitors were associated with 
the presence of DDIs, as revealed by previous studies.23–26 Other baseline factors, such as degree 
of liver fibrosis, advanced fibrosis or presence of cirrhosis, hepatocarcinoma, liver transplantation 
or impaired renal function, did not affect the incidence of DDIs in our study. It is important to 
highlight the repercussion that ART has on the presence of DDIs in our study; in this sense, the 
current recommendations on the treatment of HCV4 5 emphasise that an ART assessment of the co-
infected HIV–HCV patient should be performed due to the interactions derived from the inhibition 
or induction of CYP450, involved in the pharmacokinetics of ART and DAAs. This is especially 
significant when HIV treatment includes protease inhibitors or ART enhancers.27–30 However, the 
recent changes in relation to recommended drugs for the treatment of HIV,31 32 that positioned HIV 
integrase inhibitors as preferred, potentially reduce the incidence of DDIs with DAAs, as the 
results of this study show. Another subgroup of hepatitis C-infected patients with special attention 
in relation to DDIs are patients with chronic kidney disease and renal or hepatic transplant 
patients.33–35 This is due to the elimination routes of immunosuppressants used to avoid organ 
rejection; however, our study did not detect a higher prevalence of DDIs in patients with impaired 
renal function, or liver transplant patients.  
 
Proton pump inhibitors are the therapeutic group which causes most DDIs, specifically 
omeprazole. Previous studies of this specific interaction reveal that an adequate identification and 
follow-up of the recommendations in relation to their temporary suspension, substitution or 
administration schedule adjustment will not affect the effectiveness of the antiviral treatment.36 37 
Other medications related to the detection of DDIs in this study are those related to the 
cardiovascular system and the psycholeptics; an adequate control of blood pressure by dose 
adjustment of antihypertensive agents and the temporary suspension of lipid-lowering agents has 
allowed the control of the pathology of these patients.  
 
According to our study’s data, an adequate DDI identification, evaluation and implementation of 
the recommendations indicated for each DDI detected in all patients did not affect the antiviral 
effectiveness or therapeutic safety of hepatitis C-infected patients on DAA treatment. SVR12 rates 
in this study were very high and very similar in patients with or without DDIs; the same occurs 
with secondary efficacy variables, such as non-response or virological recurrence. In this sense, 
although several studies have evaluated the presence of DDIs in real clinical practice,22 38–40 very 
few have analysed the impact on the general safety of the treatment or the antiviral effectiveness; 
the results of the study by Ottman et al22 show no differences in SVR12 between patients who 
have at least one DDI versus those who do not have interactions. In relation to therapeutic safety, 
we can affirm that there is no clinically significant difference in the treatment safety between 
patients with and without DDIs. We have observed that although DDIs statistically increase the 
rate of patients with adverse events, these are of a mild nature and do not cause the DAA or 
concomitant treatment withdrawal, or admission to the emergency room or hospitalisation of the 
patient, or his/her death. Also, the type and frequency of the most characteristic adverse effects are 
similar in the two cohorts.  
 
This is the first study to analyse the influence of detection, evaluation and management of DDIs on 
DAA and concomitant treatment, not only in terms of the antiviral effectiveness but also of 
therapeutic safety in hepatitis C-infected patients. It has the strengths of being a prospective, 
comparative study with more than 1000 patients analysed. Among the limitations is that it is a 
unicentric study, so the demographic characteristics and localhealthcare practice could have had an 
influence on the observedresults. 
 
In conclusion, a significant percentage of hepatitis C-infected patients receiving DAA treatment 
presented clinically significant DDIs with their concomitant treatment. Being over 64 years of age 
and starting antiviral treatment based on protease inhibitors led to a higher incidence of DDIs. No 
clinical differences were observed between antiviral effectiveness and therapeutic safety among 
patients with or without clinically significant DDIs. Pharmaceutical care from clinical pharmacists 
specialising in clinical virology in a multidisciplinary team allows not only the detection or 
evaluation of detected DDIs, but also the implementation of all the therapeutic recommendations 
in the hepatitis C-infected patient, helping to preserve the high levels of effectiveness and safety of 
these treatments.  
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